Sudeep Pharma IPO – Complete Details, Strengths, Risks, Dates, Lot Size & Review (2025)
The Sudeep Pharma IPO is one of the notable public issues in 2025, coming from a long-established chemical and specialty ingredients manufacturer in India. The company specializes in high-quality excipients and specialty ingredients used across pharmaceutical, food, and nutrition industries.
This article covers all important details including IPO dates, strengths, risks, financial performance, lot size, price band, and key FAQs — fully SEO-optimized and compliant with Google guidelines.
1. Sudeep Pharma IPO – Key Details
| Particular | Value |
|---|---|
| IPO Type | Equity |
| Bidding Dates | 21 Nov – 25 Nov 2025 |
| Price Band | ₹563 – ₹593 |
| Minimum Investment | ₹14,075 |
| Lot Size | 25 Shares |
| Tentative Allotment Date | 26 Nov 2025 |
| Tentative Listing Date | 28 Nov 2025 |
| Face Value | ₹1 |
| Registrar | KFin Technologies (as shown in screenshot: K-RHP PDF2) |
| Founded | 1989 |
| MD/CEO | Mr. Sujit Jayasukh Bhayani |
| Parent Organisation | Sudeep Pharma Ltd |
2. About Sudeep Pharma Ltd
Sudeep Pharma is a technology-led manufacturer that produces excipients and specialty ingredients used in:
-
Pharmaceuticals
-
Nutraceuticals
-
Food and beverages
-
Fast-moving consumer goods (FMCG)
The company develops its products using in-house innovative processes and has a track record of more than three decades in specialty chemical manufacturing. Sudeep Pharma's solutions are used by Fortune 500 companies, multinational corporations, and more than 1,000 customers globally.
3. Strengths of Sudeep Pharma
✔ 1. Leading Manufacturer in India
Sudeep Pharma is one of India's leading manufacturers of mineral-based pharmaceutical and food-grade ingredients such as:
-
Phosphate-based excipients
-
Encapsulated preservatives
-
Calcium compounds, etc.
The company operates with more than 100 products, supported by strong research and advanced technology.
✔ 2. Strong Global Customer Base
-
More than 1,000 customers worldwide
-
Over 40 multinational companies use their products
-
Supplies to major FMCG, pharma & nutrition brands
This strong customer base ensures stable long-term demand.
✔ 3. Advanced Manufacturing Capacity
The company operates four manufacturing facilities in Vadodara with:
-
12 production lines
-
Automated processes like spray drying, encapsulation, granulation, etc.
-
Combined capacity of 72,246 metric tonnes per annum (as of June 30, 2025)
Their facilities are approved by global authorities, including:
-
US FDA (Food and Drug Administration) for certain mineral-based ingredients
-
Strict compliance and quality adherence
✔ 4. Strong R&D Infrastructure
Sudeep Pharma runs a modern R&D center with 41 professionals and advanced machinery for:
-
Fluid-bed coating
-
Spray drying
-
Tableting systems
-
Nutrient bioavailability enhancement
-
Targeted ingredient delivery
Over the last 3 years, they completed 428 R&D projects and commercialized 127 new products.
✔ 5. Consistent Revenue & Profit Growth
Revenue from operations:
-
₹428.74 Cr → FY23
-
₹450.28 Cr → FY24
-
₹502.00 Cr → FY25
Profit after tax (PAT):
-
₹63.82 Cr → FY23
-
₹131.19 Cr → FY24
-
₹138.96 Cr → FY25
This shows strong financial growth and operational efficiency.
4. Risks Associated With Sudeep Pharma IPO
⚠ 1. Customer Concentration Risk
The company relies heavily on a few key customers.
If any major client reduces orders, business could be affected.
⚠ 2. Raw Material Price Dependence
The company uses phosphate and mineral-based raw materials.
Volatility in raw material prices can directly impact profitability.
⚠ 3. Export Dependency
Exports accounted for 16–17% of total revenue in recent years.
Global regulatory changes or geopolitical issues may affect export performance.
⚠ 4. Environmental & Regulatory Compliance
Chemical manufacturing is regulated strictly.
Any violation or delay in compliance can lead to penalties or shutdowns.
⚠ 5. Outstanding Litigations
The company has pending legal cases against employees, shareholders, and others.
Any negative judgment may impact finances.
⚠ 6. Financial Indebtedness
As of September 30, 2025, the company has outstanding borrowings.
High debt may impact future cash flows.
5. Sudeep Pharma Financials (As per Screenshot)
Revenue Trend
-
2023: ~428 Cr
-
2024: ~450 Cr
-
2025: ~502 Cr
Total Assets
Steady growth across 2023–2025.
Profit
Strong upward trend, crossing ₹138 Cr in FY25.
These numbers indicate robust financial health.
6. Sudeep Pharma IPO Lot Size & Investment
| Category | Lot Size | Amount |
|---|---|---|
| Retail Investor | 1 lot (25 shares) | ₹14,075 (approx) |
| HNI (Small) | 2 lots (50 shares) | ₹28,150+ |
| HNI (Big) | Up to ₹5 lakh | Multiple lots |
7. Important Sudeep Pharma IPO Dates
| Event | Date |
|---|---|
| IPO Opens | 21 Nov 2025 |
| IPO Closes | 25 Nov 2025 |
| Allotment Date | 26 Nov 2025 |
| Refunds | 27 Nov 2025 |
| Demat Transfer | 27 Nov 2025 |
| Listing Date | 28 Nov 2025 |
8. Sudeep Pharma IPO FAQs
1. What is the issue size of Sudeep Pharma IPO?
Issue size is ₹850 crore (as per screenshot).
2. When will the IPO open?
From 21 Nov to 25 Nov 2025.
3. What is the price band?
₹563 – ₹593 per share.
4. Minimum lot size?
25 shares.
5. Where will the shares be listed?
On BSE and NSE.
6. Who is the registrar?
KFin Technologies (based on RHP PDF reference).
9. Should You Apply for Sudeep Pharma IPO? (Neutral Summary)
Positives:
-
Strong financial growth
-
Four modern manufacturing plants
-
Huge customer base including MNCs
-
Rapid product development & R&D success
-
Growing demand for specialty ingredients globally
Risks:
-
High raw material dependence
-
Heavy customer concentration
-
Regulatory & environmental compliance pressure
-
Existing legal disputes
Overall, the IPO appears fundamentally strong but investors should assess risk tolerance before investing.
Conclusion
The Sudeep Pharma IPO (2025) is a major opportunity in the specialty chemicals and excipients industry. With strong financials, a wide product portfolio, and global clients, the company has shown consistent growth — but risks remain due to regulatory and material price factors.
Investors looking for long-term specialty chemical exposure may find this IPO attractive after reviewing personal risk appetite.
Sudeep Pharma IPO – Short Summary (2025)
Sudeep Pharma Ltd, a well-established manufacturer of excipients and specialty ingredients, is launching its IPO between 21 November to 25 November 2025. The company produces high-quality pharmaceutical, nutraceutical, and food-grade ingredients using advanced, in-house technologies.
The IPO price band is ₹563–₹593, with a minimum lot size of 25 shares, requiring an investment of approximately ₹14,075. The shares are expected to be listed on 28 November 2025.
Founded in 1989, Sudeep Pharma serves 1,000+ global customers, including multinational corporations and Fortune 500 companies. It operates four modern manufacturing facilities with 12 production lines and a combined capacity of 72,246 MTPA. Their R&D team has completed 428+ projects and commercialized 127 new products, showing strong innovation capability.
Financially, the company has shown consistent growth, with revenues rising from ₹428 Cr (FY23) to ₹502 Cr (FY25), and profits increasing from ₹63 Cr to ₹138 Cr in the same period. Key risks include dependency on major customers, raw material price fluctuations, environmental regulations, and ongoing legal cases.
Overall, Sudeep Pharma’s IPO appears strong for long-term investors seeking exposure to the specialty chemicals and pharmaceutical ingredients sector.
Sudeep Pharma IPO , IPO Price , Bidding Dates , Price Band , Listing Date , Lot size , Ipo Allotment date ,
Comments
Post a Comment